Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma

BACKGROUND: Advances in tumor immunotherapy have been developed for patients with advanced recurrent or metastatic (R/M) HNSCC. However, the response of most HNSCC patients to immune checkpoint inhibitors (ICI) remains unsatisfactory. CD73 is a promising target for tumor immunotherapy, but its role...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Ao, Ye, Yafen, Chen, Fan, Xu, Yunyun, Zhang, Zhen, Zhao, Qi, Zeng, Zhao-lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708745/
https://www.ncbi.nlm.nih.gov/pubmed/36466881
http://dx.doi.org/10.3389/fimmu.2022.969034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708745/
https://www.ncbi.nlm.nih.gov/pubmed/36466881
http://dx.doi.org/10.3389/fimmu.2022.969034

Ejemplares similares